**Supplement 1**

|  |
| --- |
| **Table S1** Patient characteristics of propensity-score matched Crohn’s disease patients |
|  |  | IMM non-user(N=313) | IMMuser(N=313) |  | anti-TNFαnon-user(N=118) | anti-TNFαuser(N=118) |  |
| **Agea**  | mean (SD) | 35.2 (14.7) | 35.5 (14.9) | *p=*0.83 | 36.9 (15.2) | 34.7 (15.2) | *p=*0.26 |
| **Sex - male** | N (%) | 103 (32.9) | 104 (33.2) | *p=*0.99 | 38 (32.2) | 35 (29.7) | *p*=0.78 |
| **Current smokerα,b**  | N (%) | 139 (51.1) | 137 (48.2) | *p=*0.55 | 44 (40.0) | 50 (48.1) | *p=*0.27 |
| **Disease duration in years** | median (IQR) | 9.8 (5.4-15.1) | 5.8 (3.9-9.0) | *p*<0.01 | 7.1 (4.2-12.3) | 4.8 (3.4-6.6) | *p*<0.01 |
|  |  |  |  |  |  |  |  |
| **Disease locationa.c** |  |  |  | *p=*0.31 |  |  | *p=*0.85 |
|  | L1 – ileal location | N (%) | 138 (44.1) | 123 (39.3) |  | 39 (33.1) | 36 (30.5) |  |
|  | L2 – colon location | N (%) | 105 (33.5) | 101 (32.3) |  | 39 (33.1) | 43 (36.4) |  |
|  | L3 – ileocolon location | N (%) | 69 (22.0) | 86 (27.5) |  | 40 (33.9) | 39 (33.1) |  |
|  | L4 – only upper GI location | N (%) | 1 (0.3) | 3 (1.0) |  | - | - |  |
|  |  |  |  |  |  |  |  |
| **Disease behaviora,c** |  |  |  | *p=*0.82 |  |  | *p=*0.92 |
|  | B1 – inflammatory disease | N (%) | 220 (70.3) | 226 (72.2) |  | 80 (67.8) | 82 (69.5) |  |
|  | B2 – stricturing disease | N (%) | 56 (17.9) | 50 (16.0) |  | 25 (21.2) | 22 (18.6) |  |
|  | B3 – penetrating disease | N (%) | 37 (11.8) | 37 (11.8) |  | 13 (11.0) | 14 (11.9) |  |
|  |  |  |  |  |  |  |  |
| **Perianal disease (+*p*)a,c**  | N (%) | 29 (9.3) | 23 (7.3) | *p=*0.47 | 16 (13.6) | 15 (12.7) | *p*=0.99 |
| **Upper GI location (+*L4*)a,c**  | N (%) | 34 (10.9) | 42 (13.4) | *p=*0.39 | 20 (16.9) | 20 (16.9\_ | *p*=1.00 |

**anti-TNFα: anti tumor necrosis factor α a at diagnosis
b smoking status could not be retrieved in 169 cases**c **disease phenotype according to the Montreal consensus**

|  |
| --- |
| **Table S2** Patient characteristics of propensity-score matched ulcerative colitis patients |
|  |  | IMM non-user(N=114) | IMMuser(N=114) |  | anti-TNFαnon-user(N=28) | anti-TNFαuser(N=28) |  |
| **Agea**  | mean (SD) | 43.2 (17.3) | 42.6 (16.2) | *p=*0.80 | 42.2 (15.1) | 41.1 (17.4) | *p=*0.81 |
| **Sex - male** | N (%) | 63 (55.3) | 63 (55.3) | *p=*1.00 | 14 (50.0) | 14 (50.0) | *p*=1.00 |
| **Disease duration in years** | median (IQR) | 8.7 (5.6-15.4) | 6.3 (3.4-10.4) | *p*<0.01 | 9.2 (5.0-14.1) | 3.1 (2.2-3.8) | *p*<0.01 |
|  |  |  |  |  |  |  |  |
| **Disease locationa.c** |  |  |  | *p=*0.80 |  |  | *p=*0.77 |
|  | E1 – proctitis | N (%) | 17 (15.0) | 13 (11.4) |  | 6 (21.4) | 5 (17.9) |  |
|  | E2 – left-sided disease | N (%) | 55 (48.7) | 51 (44.7) |  | 16 (57.1) | 14 (50.0) |  |
|  | E3 – extensive disease | N (%) | 41 (36.3) | 50 (43.9) |  | 6 (21.4) | 9 (32.1) |  |

**anti-TNFα: anti tumor necrosis factor α a at diagnosis**b **disease location according to the Montreal consensus
c disease location could not be retrieved in 13 cases
smoking data were not available for UC patients**